BRAF and cancer: Targeted genetic profiling of all polyps for 15 established cancer-associated genes (TruSight®Tumor15, Illumina) confirmed the BRAF V600E and KRAS G12D mutations in 5 (46%) and one (9%) polyps, respectively.